『The Hillman Letter Podcast』のカバーアート

The Hillman Letter Podcast

The Hillman Letter Podcast

著者： Andrew Jonathan Hillman
無料で聴く

概要
 Plain English episodes from Andrew Hillman, Dallas, a Senior Paralegal and healthcare compliance expert witness retained through counsel. Topics include healthcare fraud and abuse law, The Hillman Letter, his published work and his giving record. Educational only. Not legal advice. Andrew Hillman is not an attorney. Narrated by an AI voice (synthetic narration). No real person's voice or likeness is used. Links and resources: Podcast home: https://andrew-hillman.com/podcast/ About the host: https://andrew-hillman.com/who-is-andrew-jonathan-hillman/ LinkedIn: https://www.linkedin.com/in/andrew-hillman-dallas The Hillman Letter on Substack: https://thehillmanletter.substack.com Apple Podcasts: https://podcasts.apple.com/us/podcast/the-hillman-letter-podcast/id6825615190 Spotify: https://open.spotify.com/show/2ZYUBaVrUxWDAhskCNTXzs YouTube playlist: https://www.youtube.com/playlist?list=PLElpO9MC9VC4 Academia.edu, SMU: https://smu.academia.edu/AndrewHillman ORCID: https://orcid.org/0009-0001-5396-321X Wikipedia: https://en.wikipedia.org/wiki/Andrew_Jonathan_Hillman Book a call: https://calendly.com/ajhusa Educational only. Not legal advice. Not an attorney.© 2026 Andrew Hillman マネジメント マネジメント・リーダーシップ 経済学
エピソード
  • Zero Was True. The Claim Was Still False.

    Zero Was True. The Claim Was Still False.
    2026/11/04
    On October 27, 2026, the U.S. Attorney's Office in Massachusetts announced that six SNG dialysis centers in Texas agreed to pay approximately $2 million to resolve False Claims Act allegations tied to the Provider Relief Fund. The centers admit they had closed or sold operations before reporting to HRSA, then reported zero revenue. Andrew Hillman walks through why a true number placed in the wrong context drew FCA exposure, how the Escobar half-truth theory fits, and a six-point checklist for any federal report filed after a sale or closure. Hosted by Andrew Jonathan Hillman, Dallas, Texas. Read the Letter: https://thehillmanletter.substack.com/p/zero-was-true-the-claim-was-still Main site: https://andrew-hillman.com/ Takeaways: - The centers admit each had stopped operating or sold its operations before reporting to HRSA, and each reported zero revenue. - Per the release, that created the false implication that the pandemic, not a pre-arranged sale or closure, drove revenue to zero. - The United States contends the centers submitted false claims for payment and false statements material to a false claim (31 U.S.C. 3729(a)(1)(A) and (B)). - Escobar: half-truths are representations that state the truth only so far as it goes while omitting critical qualifying information. - Sankar Nephrology Group, the majority owner, guarantees the settlement payment. - Federal reporting duties tied to past funding do not end at closing. Chapters: 0:00 Cold open 0:22 What happened 2:32 Why it matters 5:20 Practical checklist 6:58 My take 7:36 Disclaimer and close Sources: USAO-MA press release, Oct 27, 2026: https://www.justice.gov/usao-ma/pr/dialysis-centers-agree-pay-2-million-resolve-allegations-provider-relief-fund-fraud False Claims Act, 31 U.S.C. 3729 (GovInfo): https://www.govinfo.gov/content/pkg/USCODE-2023-title31/html/USCODE-2023-title31-subtitleIII-chap37-subchapIII-sec3729.htm Universal Health Services v. United States ex rel. Escobar, 579 U.S. 176 (2016), bound volume (PDF): https://www.supremecourt.gov/opinions/boundvolumes/579bv.pdf This episode is educational commentary and is not legal advice. Andrew Hillman is not an attorney. Talk to qualified counsel about your specific situation. The claims resolved in this settlement are allegations, except for facts the parties admitted. Narrated by an AI voice (synthetic narration). No real person's voice or likeness is used. Links and resources: The Letter: https://thehillmanletter.substack.com/p/zero-was-true-the-claim-was-still Podcast home: https://andrew-hillman.com/podcast/ About the host: https://andrew-hillman.com/who-is-andrew-jonathan-hillman/ LinkedIn: https://www.linkedin.com/in/andrew-hillman-dallas The Hillman Letter on Substack: https://thehillmanletter.substack.com Apple Podcasts: https://podcasts.apple.com/us/podcast/the-hillman-letter-podcast/id6825615190 YouTube playlist: https://www.youtube.com/playlist?list=PLElpO9MC9VC4 Academia.edu, SMU: https://smu.academia.edu/AndrewHillman ORCID: https://orcid.org/0009-0001-5396-321X Wikipedia: https://en.wikipedia.org/wiki/Andrew_Jonathan_Hillman Book a call: https://calendly.com/ajhusa Educational only. Not legal advice. Not an attorney.
    続きを読む 一部表示
    8 分
  • 1.25–1.6x Beats Treble: The Six-Month FCA Self-Disclosure Window

    1.25–1.6x Beats Treble: The Six-Month FCA Self-Disclosure Window
    2026/10/26
    On October 22, 2026, the Justice Department's Civil Division and HHS launched the Healthcare False Claims Act Self-Disclosure Pilot Program (FCA SDPP). It offers healthcare companies a coordinated civil release for disclosing potential FCA violations previously unknown to the government, at a repayment of 1.25 to 1.6 times a base amount instead of the FCA's treble damages. Andrew Hillman walks through what the protocol says, why the math matters and a nine-point operator checklist for the six-month window, which closes at 11:59 PM on April 22, 2027. Hosted by Andrew Jonathan Hillman, Dallas, Texas. Read the Letter: https://thehillmanletter.substack.com/p/fca-self-disclosure-pilot Main site: https://andrew-hillman.com/ Takeaways: - Repayment is 1.25 to 1.6 times the Base Self-Disclosure Repayment. The FCA allows up to three times damages plus per-claim penalties. - The gate is "previously unknown to the federal government." If the government already knows, the pilot is off the table. - Civil only. Potential criminal conduct goes to DOJ's National Fraud Enforcement Division under a separate policy. - Submissions go to FCA-SDPP@usdoj.gov by 11:59 PM on April 22, 2027. Late or partial submissions will not be accepted or reviewed. - The 60-day overpayment rule at 42 C.F.R. 401.305 keeps running. Chapters: 0:00 Cold open 0:27 What happened 4:55 Why it matters 7:57 Practical checklist 10:13 My take 10:48 Disclaimer and close Sources: DOJ/HHS FCA SDPP protocol (PDF): https://www.justice.gov/opa/media/1467546/dl DOJ press release, Oct 22, 2026: https://www.justice.gov/opa/pr/justice-departments-civil-division-and-department-health-human-services-announce-anti-fraud HHS press release, Oct 22, 2026: https://www.hhs.gov/press-room/hhs-doj-launch-healthcare-false-claims-act-self-disclosure-pilot.html This episode is educational commentary and is not legal advice. Andrew Hillman is not an attorney. Talk to qualified counsel about your specific situation. Narrated by an AI voice (synthetic narration). No real person's voice or likeness is used. Links and resources: The Letter: https://thehillmanletter.substack.com/p/fca-self-disclosure-pilot Podcast home: https://andrew-hillman.com/podcast/ About the host: https://andrew-hillman.com/who-is-andrew-jonathan-hillman/ LinkedIn: https://www.linkedin.com/in/andrew-hillman-dallas The Hillman Letter on Substack: https://thehillmanletter.substack.com Apple Podcasts: https://podcasts.apple.com/us/podcast/the-hillman-letter-podcast/id6825615190 Spotify: https://open.spotify.com/show/2ZYUBaVrUxWDAhskCNTXzs YouTube episode: https://www.youtube.com/watch?v=G2yFNQTmNQA YouTube playlist: https://www.youtube.com/playlist?list=PLElpO9MC9VC4 Academia.edu, SMU: https://smu.academia.edu/AndrewHillman ORCID: https://orcid.org/0009-0001-5396-321X Wikipedia: https://en.wikipedia.org/wiki/Andrew_Jonathan_Hillman Book a call: https://calendly.com/ajhusa Educational only. Not legal advice. Not an attorney.
    続きを読む 一部表示
    12 分
  • Glass, Cold Chain and the Law: The 351(a) Classification of Wharton's Jelly Exosomes

    Glass, Cold Chain and the Law: The 351(a) Classification of Wharton's Jelly Exosomes
    2026/10/21
    Andrew Hillman's 2026 manuscript on why Wharton's jelly stem cell exosomes require BLA licensure under Section 351(a), and what that classification means for manufacturing. We cover the four-criteria test, cGMP and ISO and ICH quality systems, Type I glass, the minus 80 degree cold chain, and the labeling problems the paper sees in grey market products. Exosome products are not approved by the FDA for any indication. Hosted by Andrew Jonathan Hillman, Dallas, Texas. Permanent record (DOI): https://doi.org/10.5281/zenodo.21169929 Main site: https://andrew-hillman.com/ Publications: https://andrew-hillman.com/publications/ This episode is educational and is not legal or medical advice. Andrew Hillman is not an attorney. Narrated by an AI voice (synthetic narration). No real person's voice or likeness is used. Links and resources: Companion paper: https://andrew-hillman.com/publications/whartons-jelly-msc-exosomes-351a-classification/ Podcast home: https://andrew-hillman.com/podcast/ About the host: https://andrew-hillman.com/who-is-andrew-jonathan-hillman/ LinkedIn: https://www.linkedin.com/in/andrew-hillman-dallas The Hillman Letter on Substack: https://thehillmanletter.substack.com Apple Podcasts: https://podcasts.apple.com/us/podcast/the-hillman-letter-podcast/id6825615190 Spotify: https://open.spotify.com/show/2ZYUBaVrUxWDAhskCNTXzs YouTube playlist: https://www.youtube.com/playlist?list=PLElpO9MC9VC4 Academia.edu, SMU: https://smu.academia.edu/AndrewHillman ORCID: https://orcid.org/0009-0001-5396-321X Wikipedia: https://en.wikipedia.org/wiki/Andrew_Jonathan_Hillman Book a call: https://calendly.com/ajhusa Educational only. Not legal advice. Not an attorney.
    続きを読む 一部表示
    7 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません